Drug intelligence / Profile preview

loperamide + golden bifid

Development stage: Unknown
Lead developer: Janssen Pharmaceutica
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Loperamide + golden bifid is a combination therapy consisting of loperamide, a synthetic opioid antidiarrheal agent, and golden bifid, a probiotic preparation. Loperamide acts as an agonist at μ-opioid receptors in the myenteric plexus of the large intestine, slowing intestinal motility and reducing diarrhea by increasing absorption of fluids and electrolytes[3][4][6][8]. Golden bifid is a probiotic formulation containing beneficial bacteria (commonly Bifidobacterium species), intended to restore or maintain healthy gut flora balance. This combination has been studied for prevention and treatment of drug-induced diarrhea (e.g., pyrrolitinib-associated diarrhea) in clinical settings[2]. The rationale is that loperamide provides rapid symptomatic relief while golden bifid supports gut microbiota health.

Targets

DOR (Opioid Receptor Delta 1)MOR (Mu opioid receptor)KOR (Kappa opioid receptor)

Beyond the preview

Go deeper on loperamide + golden bifid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on loperamide + golden bifid.

Explore the full profile